山东大学耳鼻喉眼学报 ›› 2024, Vol. 38 ›› Issue (1): 122-127.doi: 10.6040/j.issn.1673-3770.0.2022.515

• 综述 • 上一篇    下一篇

新型冠状病毒与眼科相关研究进展

丁晓敏1,2,崔彦1   

  1. 1.山东大学齐鲁医院 眼科, 山东 济南 250012;
    2.山东大学 第一临床学院, 山东 济南 250012
  • 发布日期:2024-01-12
  • 通讯作者: 崔彦. E-mail:cyeleanor@163.com

Advances in severe acute respiratory syndrome coronavirus 2 study about ophthalmology

DING Xiaomin1,2, CUI Yan1   

  1. 1. Department of Ophthalmology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China2. The First Clinical College of Shandong University, Jinan 250012, Shandong, China
  • Published:2024-01-12

摘要: 新型冠状病毒感染(corona virus disease 2019,COVID-19)是由严重急性呼吸综合征冠状病毒-2(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)引起的急性感染性肺炎。目前临床已有较多病例报告提示COVID-19患者也可表现出眼部症状,同时在新型冠状病毒疫苗的应用过程中亦出现了各种眼部不良事件。论文通过回顾国内外相关文献及研究,探讨SARS-CoV-2经眼传播的可能性、眼部受累表现、治疗方案以及接种COVID-19疫苗后可能出现的眼部不良事件,并为眼科医务人员的临床防护给出建议。

关键词: 新型冠状病毒感染, 结膜炎, 视网膜血管病变, 脉络膜, 闭角型青光眼

Abstract: Corona virus disease 2019(COVID-19)is an acute infectious pneumonia caused by the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2). Previous reports have suggested that patients with COVID-19 may also exhibit ocular symptoms, and some ophthalmic adverse events have been reported after COVID-19 vaccination. Based on the recent literature and existing studies, this study aims to discuss the possibility of ophthalmic infections due to SARS-CoV-2, the ocular signs, treatments and possible ocular adverse events after COVID-19 vaccination, and provide references to the ophthalmologists for prevention and control.

Key words: Corona virus disease 2019, Conjunctivitis, Retinal vasculopathy, Choroid, Angle-closure glaucoma

中图分类号: 

  • R77
[1] Chen NS, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020, 395(10223): 507-513. doi:10.1016/S0140-6736(20)30211-7
[2] Lu HZ, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle[J]. J Med Virol, 2020, 92(4): 401-402. doi:10.1002/jmv.25678
[3] Wu P, Duan F, Luo CH, et al. Characteristics of ocular findings of patients with coronavirus disease 2019(COVID-19)in Hubei Province, China[J]. JAMA Ophthalmol, 2020, 138(5): 575-578. doi:10.1001/jamaophthalmol.2020.1291
[4] Ocansey S, Abu EK, Abraham CH, et al. Ocular symptoms of SARS-CoV-2: indication of possible ocular transmission or viral shedding[J]. Ocul Immunol Inflamm, 2020, 28(8): 1269-1279. doi:10.1080/09273948.2020.1799035
[5] Xia JH, Tong JP, Liu MY, et al. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection[J]. J Med Virol, 2020, 92(6): 589-594. doi:10.1002/jmv.25725
[6] Belser JA, Rota PA, Tumpey TM. Ocular tropism of respiratory viruses[J]. Microbiol Mol Biol Rev, 2013, 77(1): 144-156. doi:10.1128/MMBR.00058-12
[7] Seah I, Agrawal R. Can the coronavirus disease 2019(COVID-19)affect the eyes? A review of coronaviruses and ocular implications in humans and animals[J]. Ocul Immunol Inflamm, 2020, 28(3): 391-395. doi:10.1080/09273948.2020.1738501
[8] 季樱红, 孙杨, 卢奕. 新型冠状病毒的眼睛侵入途径与眼科防护重点[J]. 中国眼耳鼻喉科杂志, 2020, 20(3): 156-161.doi: 10.14166/j.issn.1671-2420.2020.03.003 JI Yinghong, SUN Yang, LU Yi. Eye invasion route of 2019 novel corona virus and the emphasis of ophthalmic protection[J]. Chinese Journal of Ophthalmology and otorhinolaryngology, 2020, 20(3): 156-161.doi: 10.14166/j.issn.1671-2420.2020.03.003
[9] Imai Y, Kuba K, Ohto-Nakanishi T, et al. Angiotensin-converting enzyme 2(ACE2)in disease pathogenesis[J]. Circ J, 2010, 74(3): 405-410. doi:10.1253/circj.cj-10-0045
[10] Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus[J]. Nature, 2003, 426(6965): 450-454. doi: 10.1038/nature02145
[11] Deng W, Bao LL, Gao H, et al. Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques[J]. Nat Commun, 2020, 11(1): 4400. doi:10.1038/s41467-020-18149-6
[12] Hui KPY, Cheung MC, Perera RAPM, et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures[J]. Lancet Respir Med, 2020, 8(7): 687-695. doi:10.1016/S2213-2600(20)30193-4
[13] Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study[J]. Lancet, 2022, 399(10335): 1618-1624. doi:10.1016/S0140-6736(22)00327-0
[14] Guan WJ, Zhong NS. Clinical Characteristics of Covid-19 in China. Reply[J]. N Engl J Med, 2020, 382(19): 1861-1862. doi:10.1056/NEJMc2005203
[15] Wu P, Liang L, Chen CB, et al. A child confirmed COVID-19 with only symptoms of conjunctivitis and eyelid dermatitis[J]. Graefes Arch Clin Exp Ophthalmol, 2020, 258(7): 1565-1566. doi:10.1007/s00417-020-04708-6
[16] Navel V, Chiambaretta F, Dutheil F. Haemorrhagic conjunctivitis with pseudomembranous related to SARS-CoV-2[J]. Am J Ophthalmol Case Rep, 2020, 19: 100735. doi:10.1016/j.ajoc.2020.100735
[17] Méndez Mangana C, Barraquer Kargacin A, Barraquer RI. Episcleritis as an ocular manifestation in a patient with COVID-19[J]. Acta Ophthalmol, 2020, 98(8): e1056-e1057. doi:10.1111/aos.14484
[18] François J, Collery AS, Hayek G, et al. Coronavirus disease 2019-associated ocular neuropathy with panuveitis: a case report[J]. JAMA Ophthalmol, 2021, 139(2): 247-249. doi:10.1001/jamaophthalmol.2020.5695
[19] Providência J, Fonseca C, Henriques F, et al. Serpiginous choroiditis presenting after SARS-CoV-2 infection: a new immunological trigger?[J]. Eur J Ophthalmol, 2022, 32(1): NP97-NP101. doi:10.1177/1120672120977817
[20] Casagrande M, Fitzek A, Püschel K, et al. Detection of SARS-CoV-2 in human retinal biopsies of deceased COVID-19 patients[J]. Ocul Immunol Inflamm, 2020, 28(5): 721-725. doi:10.1080/09273948.2020.1770301
[21] de Figueiredo CS, Raony í, Giestal-de-Araujo E. SARS-CoV-2 targeting the retina: host-virus interaction and possible mechanisms of viral tropism[J]. Ocul Immunol Inflamm, 2020, 28(8): 1301-1304. doi:10.1080/09273948.2020.1799037
[22] Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19[J]. Lancet, 2020, 395(10234): 1417-1418. doi:10.1016/S0140-6736(20)30937-5
[23] Marinho PM, Marcos AAA, Romano AC, et al. Retinal findings in patients with COVID-19[J]. Lancet, 2020, 395(10237): 1610. doi:10.1016/S0140-6736(20)31014-X
[24] Invernizzi A, Torre A, Parrulli S, et al. Retinal findings in patients with COVID-19: results from the SERPICO-19 study[J]. EClinicalMedicine, 2020, 27: 100550. doi:10.1016/j.eclinm.2020.100550
[25] Sheth JU, Narayanan R, Goyal J, et al. Retinal vein occlusion in COVID-19: a novel entity[J]. Indian J Ophthalmol, 2020, 68(10): 2291-2293. doi:10.4103/ijo.IJO_2380_20
[26] Ortiz-Seller A, Martínez Costa L, Hernández-Pons A, et al. Ophthalmic and neuro-ophthalmic manifestations of coronavirus disease 2019(COVID-19)[J]. Ocul Immunol Inflamm, 2020, 28(8): 1285-1289. doi:10.1080/09273948.2020.1817497
[27] Benito-Pascual B, Gegúndez JA, Díaz-Valle D, et al. Panuveitis and optic neuritis as a possible initial presentation of the novel coronavirus disease 2019(COVID-19)[J]. Ocul Immunol Inflamm, 2020, 28(6): 922-925. doi:10.1080/09273948.2020.1792512
[28] 中华预防医学会公共卫生眼科学分会. 中国新型冠状病毒眼病防控专家共识(2022年)[J]. 中华眼科杂志, 2022, 58(3): 176-181. doi: 10.3760/cma.j.cn112142-20211124-00561
[29] Luís ME, Hipólito-Fernandes D, Mota C, et al. A review of neuro-ophthalmological manifestations of human coronavirus infection[J]. Eye Brain, 2020, 12: 129-137. doi:10.2147/EB.S268828
[30] Tisdale AK, Chwalisz BK. Neuro-ophthalmic manifestations of coronavirus disease 19[J]. Curr Opin Ophthalmol, 2020, 31(6): 489-494. doi:10.1097/ICU.0000000000000707
[31] Ordás CM, Villacieros-álvarez J, Pastor-Vivas AI, et al. Concurrent tonic pupil and trochlear nerve palsy in COVID-19[J]. J Neurovirol, 2020, 26(6): 970-972. doi:10.1007/s13365-020-00909-1
[32] 胡明霞, 袁建明, 张彬, 等. 新型冠状病毒疫苗的研究进展[J]. 中国感染与化疗杂志, 2022, 22(4): 504-508. doi: 10.16718/j.1009-7708.2022.04.023 HU Mingxia, YUAN Jianming, ZHANG Bin, et al. Research updates on SARS-CoV-2 vaccines[J]. Chinese Journal of Infection and Chemotherapy, 2022, 22(4): 504-508. doi: 10.16718/j.1009-7708.2022.04.023
[33] Haseeb AA, Solyman O, Abushanab MM, et al. Ocular complications following vaccination for COVID-19: a one-year retrospective[J]. Vaccines(Basel), 2022, 10(2): 342. doi:10.3390/vaccines10020342
[34] Sheng QL, Sun YN, Zhai RY, et al. Posner-Schlossman syndrome relapse following inactivated COVID-19 vaccination in China[J]. Front Public Health, 2022, 10: 1051378. doi:10.3389/fpubh.2022.1051378
[35] Fraunfelder FW, Suhler EB, Fraunfelder FT. Hepatitis B vaccine and uveitis: an emerging hypothesis suggested by review of 32 case reports[J]. Cutan Ocul Toxicol, 2010, 29(1): 26-29. doi:10.3109/15569520903427717
[36] Aguirre G, Carmichael L, Bistner S. Corneal endothelium in viral induced anterior uveitis. Ultrastructural changes following canine adenovirus type 1 infection[J]. Arch Ophthalmol, 1975, 93(3): 219-224. doi:10.1001/archopht.1975.01010020227012
[37] Rabinovitch T, Ben-Arie-Weintrob Y, Hareuveni-Blum T, et al. Uveitis after the bnt162b2 mrna vaccination against sars-cov-2 infection: a possible association[J]. Retina, 2021, 41(12): 2462-2471. doi:10.1097/IAE.0000000000003277
[38] Steinemann TL, Koffler BH, Jennings CD. Corneal allograft rejection following immunization[J]. Am J Ophthalmol, 1988, 106(5): 575-578. doi:10.1016/0002-9394(88)90588-0
[39] Abousy M, Bohm K, Prescott C, et al. Bilateral EK rejection after COVID-19 vaccine[J]. Eye Contact Lens, 2021, 47(11): 625-628. doi:10.1097/ICL.0000000000000840
[40] Bøhler AD, Strøm ME, Sandvig KU, et al. Acute macular neuroretinopathy following COVID-19 vaccination[J]. Eye(Lond), 2022, 36(3): 644-645. doi: 10.1038/s41433-021-01610-1
[41] Pichi F, Aljneibi S, Neri P, et al. Association of ocular adverse events with inactivated COVID-19 vaccination in patients in abu dhabi[J]. JAMA Ophthalmol, 2021, 139(10): 1131-1135. doi: 10.1001/jamaophthalmol.2021.3477
[42] Mambretti M, Huemer J, Torregrossa G, et al. Acute macular neuroretinopathy following coronavirus disease 2019 vaccination[J]. Ocul Immunol Inflamm, 2021, 29(4): 730-733. doi:10.1080/09273948.2021.1946567
[43] Elnahry AG, Al-Nawaflh MY, Gamal Eldin AA, et al. COVID-19 vaccine-associated optic neuropathy: a systematic review of 45 patients[J]. Vaccines(Basel), 2022, 10(10): 1758. doi:10.3390/vaccines10101758
[44] Eleiwa TK, Gaier ED, Haseeb A, et al. Adverse ocular events following COVID-19 vaccination[J]. Inflamm Res, 2021, 70(10/11/12): 1005-1009. doi:10.1007/s00011-021-01506-6
[45] Tsukii R, Kasuya Y, Makino S. Nonarteritic anterior ischemic optic neuropathy following COVID-19 vaccination: consequence or coincidence[J]. Case Rep Ophthalmol Med, 2021: 5126254. doi:10.1155/2021/5126254
[46] 陈博, 张宪, 孙旭芳. 新型冠状病毒防控中眼科医务人员的预防措施[J]. 国际眼科杂志, 2020, 20(3): 580-582. doi: 10.3980/j.issn.1672-5123.2020.3.41 CHEN Bo, ZHANG Xian, SUN Xufang. Precaution of SARS-CoV-2 infection in ophthalmology medical staff[J]. International Eye Science, 2020, 20(3): 580-582. doi: 10.3980/j.issn.1672-5123.2020.3.41
[47] Kampf G, Todt D, Pfaender S, et al. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents[J]. J Hosp Infect, 2020, 104(3): 246-251. doi:10.1016/j.jhin.2020.01.022
[48] Du H, Zhang M, Zhang H, et al. Practical experience on emergency ophthalmic surgery during the prevalence of COVID-19[J]. Albrecht Von Graefes Arch Fur Klinische Und Exp Ophthalmol, 2020, 258(8): 1831-1833. doi:10.1007/s00417-020-04692-x
[49] Yu AY, Tu RX, Shao X, et al. A comprehensive Chinese experience against SARS-CoV-2 in ophthalmology[J]. Eye Vis(Lond), 2020, 7: 19. doi:10.1186/s40662-020-00187-2
[50] Güemes-Villahoz N, Burgos-Blasco B, Vidal-Villegas B, et al. Novel insights into the transmission of SARS-CoV-2 through the ocular surface and its detection in tears and conjunctival secretions: a review[J]. Adv Ther, 2020, 37(10): 4086-4095. doi:10.1007/s12325-020-01442-7
[1] 王剑,杜伟嘉,薛涛,陈福权. 利用百度指数分析中国过敏性鼻炎及相关变应性疾病的流行特征[J]. 山东大学耳鼻喉眼学报, 2023, 37(5): 31-41.
[2] 张晓晗,魏丽,杨凯莉,陈海燕,李彦松,王平. 中医辨证论治前后CSC患者OCTA变化及其与视力的相关性研究[J]. 山东大学耳鼻喉眼学报, 2023, 37(5): 115-122.
[3] 赵露,田慧文,孟博,王薇,王艳玲. 颈内动脉闭塞患者黄斑区视网膜脉络膜厚度变化分析[J]. 山东大学耳鼻喉眼学报, 2023, 37(3): 72-76.
[4] 尤冉,郭笑霄,王薇,陈曦,王艳玲. 高度近视患者黄斑区视网膜劈裂分型与脉络膜特征分析[J]. 山东大学耳鼻喉眼学报, 2023, 37(3): 83-87.
[5] 李璐,赵杰,赵博军. 中心性浆液性脉络膜视网膜病变的发病机制与治疗研究进展[J]. 山东大学耳鼻喉眼学报, 2023, 37(3): 118-124.
[6] 徐恩沛,孙先勇. 渗出性年龄相关性黄斑变性并发视网膜色素上皮脱离的诊治进展[J]. 山东大学耳鼻喉眼学报, 2023, 37(3): 125-142.
[7] 唐慧新,李景景,邹红. 阈值下微脉冲激光光凝作用机制及临床应用[J]. 山东大学耳鼻喉眼学报, 2023, 37(3): 143-148.
[8] 初宝睿,曲毅. 载siIKKβ脂质纳米粒的制备及其对巨噬细胞再极化的作用[J]. 山东大学耳鼻喉眼学报, 2023, 37(2): 91-97.
[9] 熊翩翩,王佳琳,孙姣,周卓华,王艳玲. 高度近视豹纹状眼底视网膜脉络膜血流改变及相关性分析[J]. 山东大学耳鼻喉眼学报, 2023, 37(2): 114-121.
[10] 孙浩, 杨会,李姣. 后部葡萄膜黑色素瘤活检及其临床意义的研究[J]. 山东大学耳鼻喉眼学报, 2023, 37(1): 152-156.
[11] 张陶然,王薇,李明铭,黄映湘. IVR治疗mCNV患者黄斑中心凹下脉络膜厚度分析[J]. 山东大学耳鼻喉眼学报, 2022, 36(2): 68-71.
[12] 张小艳,郝晓凤,谢立科. 脉络膜骨瘤的相干光断层扫描特征的研究进展[J]. 山东大学耳鼻喉眼学报, 2021, 35(6): 138-141.
[13] 张昕雨,雷春燕,张美霞. 运用OCT及OCTA观察硅油对视网膜脉络膜的影响[J]. 山东大学耳鼻喉眼学报, 2021, 35(5): 132-136.
[14] 任雨馨,赵博军. 病理性近视脉络膜新生血管的诊断与治疗[J]. 山东大学耳鼻喉眼学报, 2020, 34(5): 157-162.
[15] 傅强,王红星. 眼缺血综合征患者脉络膜厚度的分析[J]. 山东大学耳鼻喉眼学报, 2020, 34(4): 60-63.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!